Rituximab for Idiopathic Membranous Nephropathy: Who Can Benefit?
about
Controversies in the treatment of idiopathic membranous nephropathy.Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial.Rituximab treatment for membranous nephropathy: a French clinical and serological retrospective study of 28 patients.Rituximab in children with resistant idiopathic nephrotic syndrome.Pharmacological treatment of primary membranous nephropathy in 2016.Treatment of idiopathic membranous nephropathy.A case of membranous nephropathy as a manifestation of graft-versus-host disease.Depletion of B lymphocytes in idiopathic membranous glomerulopathy: results from patients with extended follow-upLow- and high-molecular-weight urinary proteins as predictors of response to rituximab in patients with membranous nephropathy: a prospective study.Latest treatment strategies for membranous nephropathy.Partial therapeutic response to Rituximab for the treatment of chronic alloantibody mediated rejection of kidney allografts.Chronic alloantibody mediated rejection.Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patientsRituximab therapy for membranous nephropathy: a systematic reviewManagement of idiopathic membranous nephropathy.Rituximab in immunologic glomerular diseases.Childhood nephrotic syndrome--current and future therapies.Our experience with rituximab therapy for adult-onset primary glomerulonephritis and review of literature.Rituximab: emerging treatment strategies of immune-mediated glomerular disease.Rituximab therapy in nephrotic syndrome: implications for patients' management.Overview of current and alternative therapies for idiopathic membranous nephropathy.Biologics for the treatment of autoimmune renal diseases.Recurrent idiopathic membranous nephropathy in the renal allograft: successful treatment with the anti-CD20 monoclonal antibody rituximab.Single-dose Rituximab Therapy for Refractory Idiopathic Membranous Nephropathy: A Single-center Experience.Renal pathology in hematopoietic cell transplantation recipients.Rituximab in Membranous Nephropathy: Not All Studies Are Created Equal.Pathogenic role of effector cells and immunoglobulins in cationic bovine serum albumin-induced membranous nephropathy.A new rescue regimen with plasma exchange and rituximab in high-risk membranous glomerulonephritis.Low-dose Rituximab therapy in resistant idiopathic membranous nephropathy: single-center experience.A case report of remission of refractory membranous nephropathy progressing to stage 4 chronic kidney disease using low-dose rituximab: A long-term follow-up.Novel targets and new potential: developments in the treatment of inflammation in chronic kidney disease
P2860
Q34248343-420ECBC6-ADD5-4477-8026-65C23FFED4B0Q35030581-C3EEB683-8993-47F3-8764-B70B99EDF0ECQ35791799-B896B881-72C5-4659-968B-704FA2508025Q35982341-8F13E3C2-F01A-43A5-B61F-6D1B807DD783Q36106413-CD40C624-401F-4595-87C9-7DC8532A73FEQ36280345-25C8576D-30B8-40C2-9974-69E2AE900661Q36471828-802C0BA8-8168-42F0-9B40-FDA7B668AA3EQ36596888-40AA4441-9606-4A8D-B0A5-22BACF404E97Q36741001-A9421074-E76B-4222-A91A-F5E4D91A13BEQ37013035-DC67A823-382F-4125-A194-8A661DFF3B17Q37058039-ECE10D2B-2763-46FB-AF77-486EBC292984Q37058050-6FA25368-E10A-45F8-9D21-36DD7681BC65Q37211086-1B79FFC9-2309-42E7-8EA3-ED30F3B23D21Q37412829-CB90BAED-135A-4318-A408-9F5521804C91Q37779802-BFF01646-C376-43B6-82BE-9FF78CA2ECAEQ37989298-DC0D834D-D729-45FB-8FFD-47A3B4E879E0Q38017937-7CEF4191-DE4B-461D-AA52-6D9E5933A4ABQ38026511-4FE9A5BA-0D49-46D4-A113-CA1DB832EA88Q38033648-E3C87EE0-4691-4D97-9C0C-D154AAFE53B6Q38075787-84DA3493-57E2-4192-8C5B-8B40CB97BC5AQ38425865-DB24913F-BCB5-405E-BC31-C763BC2FE253Q38763327-10768AF6-90D1-45A5-8D0B-7FD40AAD32C9Q40327911-D8238452-08FD-4624-BFBE-92611381B8C7Q41073990-927BEB79-D78C-4F9D-BC7B-74C500B2F8ABQ46788671-ACF1B8C4-35D7-4C87-B634-398467449D60Q52846990-6B7A164D-0E40-4797-871B-DEB0DAAB9311Q53206105-E189A071-5A3A-421E-B811-52871D23EE97Q53324683-3A68E055-5FAD-4BF3-949F-3BC537E09805Q55287848-5F3832FA-F3A2-436A-8BF9-6D7E225D93D2Q55434137-6FFA080F-0053-47B8-8569-DF4A76B33BECQ57771987-42FC2FCE-9A80-42E1-971B-A1E65B4062DB
P2860
Rituximab for Idiopathic Membranous Nephropathy: Who Can Benefit?
description
scientific article published on 14 June 2006
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в червні 2006
@uk
name
Rituximab for Idiopathic Membranous Nephropathy: Who Can Benefit?
@en
Rituximab for Idiopathic Membranous Nephropathy: Who Can Benefit?
@nl
type
label
Rituximab for Idiopathic Membranous Nephropathy: Who Can Benefit?
@en
Rituximab for Idiopathic Membranous Nephropathy: Who Can Benefit?
@nl
prefLabel
Rituximab for Idiopathic Membranous Nephropathy: Who Can Benefit?
@en
Rituximab for Idiopathic Membranous Nephropathy: Who Can Benefit?
@nl
P2093
P50
P356
P1476
Rituximab for idiopathic membranous nephropathy: who can benefit?
@en
P2093
Carlos Chiurchiu
Mario Bontempelli
Mauro Abbate
P304
P356
10.2215/CJN.01080905
P577
2006-06-14T00:00:00Z